TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29099950

Group type: EXPERIMENTAL
Intervention: Modified Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (delayed surgery)
Number of subjects: 65
Study: 26960406

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with home medication management review
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 112
Study: 24595942

Group type: EXPERIMENTAL
Intervention: 1 g dehydrated garlic powder
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 g dehydrated garlic powder
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22265697

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg per day plus goserelin 3.6 mg/month
Number of subjects: 204

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day plus goserelin 3.6 mg/month
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 204

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 204
Study: 19576321

Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) for > or =6 months
Number of subjects: 1803
Study: 17615073

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic therapy
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Guidelines-enforced management
Number of subjects: 1002
Study: 14989794

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily)
Number of subjects: 431

Group type: COMPARATOR
Intervention: r‐hFSH alone
Number of subjects: 431

Group type: COMPARATOR
Intervention: r‐hFSH alone (<35 years)
Number of subjects: 431

Group type: COMPARATOR
Intervention: r‐hFSH alone (≥35 years)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily) (<35 years)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (150 IU daily) (≥35 years)
Number of subjects: 431
Study: 11668407

Group type: COMPARATOR
Intervention: Pure cut current alone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sequential combination of pure cut then blended current
Number of subjects: 142
Study: 9766143

Group type: EXPERIMENTAL
Intervention: Primary care projects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large scale campaigns
Number of subjects: 0
Study: 7905722

Group type: EXPERIMENTAL
Intervention: Didanosine (600 mg/d adjusted for weight)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Zidovudine (600 mg/d)
Number of subjects: 312
Study: 2733733

Group type: EXPERIMENTAL
Intervention: Protective isolation with disposable, non-waven, polypropylene gowns and nonsterile latex gloves
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study: 6581281

Group type: EXPERIMENTAL
Intervention: Diazepam titration (mean dose = 25.6 mgs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of diazepam (12.5 mg), fentanyl (0.1 mg), and methohexital (mean dose = 18.0 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of diazepam (15.0 mg) and methohexital (mean dose = 27.0 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31905090

Group type: EXPERIMENTAL
Intervention: Tolcapone (an inhibitor of catechol‐O‐methyltransferase [COMT])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine (a DA agonist with preferential affinity for the D2 receptor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30929973

Group type: EXPERIMENTAL
Intervention: CABG without prior PCI
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: CABG with prior PCI
Number of subjects: 1212

Group type: COMPARATOR
Intervention: MED (control group)
Number of subjects: 1212
Study: 29067428

Group type: EXPERIMENTAL
Intervention: Hypothermia (maintained at 33.5°C for 96 hours)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Noncooled (maintained at 37.0°C)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 168
Study: 25667241

Group type: EXPERIMENTAL
Intervention: Residential intervention (supervised diet and exercise)
Number of subjects: 33
Study: 24928269

Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane (Macroplastique)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Dextranomer/hyaluronic acid copolymer (Deflux)
Number of subjects: 275
Study: 22039289

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimantadine 100 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment of oseltamivir and rimantadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (monotherapy)
Number of subjects: 0
Study: 20054875

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study: 17433007

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonalcoholic placebo beverage (n=24)
Number of subjects: 50
Study: 16372579

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan 50 mg/HCTZ 12.5 mg
Number of subjects: 0
Study: 11890866

Group type: EXPERIMENTAL
Intervention: Immunotherapy (vaccines involving monoclonal antibodies or immune effector cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell-based therapies using tumour cells as vaccine components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune cells (e.g., T-lymphocytes and dendritic cells)
Number of subjects: 0
Study: 9815522

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 37000

Group type: EXPERIMENTAL
Intervention: Tamoxifen with chemotherapy
Number of subjects: 37000
Study: 8121974

Group type: EXPERIMENTAL
Intervention: Attention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Attention plus Expectancy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 2678686

Group type: EXPERIMENTAL
Intervention: Alpha interferons
Number of subjects: 5000
Study: 334209

Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg and 15 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hydroxyzine (75 mg and 150 mg)
Number of subjects: 70
Study: 30484730

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (delivered via Skype or face-to-face sessions)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control/care-as-usual group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 113
Study: 28150186

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161
Study: 25383558

Group type: EXPERIMENTAL
Intervention: Multitarget therapy (tacrolimus 4 mg/d and mycophenolate mofetil 1.0 g/d)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (0.75 g/m2 every 4 weeks for 6 months)
Number of subjects: 362
Study: 23816018

Group type: EXPERIMENTAL
Intervention: cTnT (fourth-generation Roche assay)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Combination of cTnT with copeptin
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT with copeptin
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: cTnT
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Combination of cTnT and copeptin
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT and copeptin
Number of subjects: 1247
Study: 21681372

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (NP chemotherapy followed by vaccination with CEA (605-613) peptide-pulsed autologous dendritic cells and CIK cells, repeated at 30-day intervals for 4 cycles)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional NP chemotherapy
Number of subjects: 28
Study: 19788736

Group type: EXPERIMENTAL
Intervention: Lyostypt
Number of subjects: 28

Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 28
Study: 17276750

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.25 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.125 mg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15352149

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25, 50, or 75 mg every 2 weeks for up to 50 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 57
Study: 11359333

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extraperitoneal approach
Number of subjects: 20
Study: 9681160

Group type: EXPERIMENTAL
Intervention: Y-connector technique (IY)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional technique (CY)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard spikes (IS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard spikes (CS)
Number of subjects: 60
Study: 8043247

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine injection
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 58
Study: 2968761

Group type: EXPERIMENTAL
Intervention: Buserelin (pernasally in conventional doses)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Decapeptyl (intramuscularly in 5-week intervals)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both LHRH analogues (Buserelin and Decapeptyl)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: PAP and PSA tumor markers
Number of subjects: 107
Study: 31735531

Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dynamic resistance exercise
Number of subjects: 21
Study: 30839075

Group type: EXPERIMENTAL
Intervention: CGAE supplementation at 1,000 mg/kg
Number of subjects: 400

Group type: COMPARATOR
Intervention: HT group
Number of subjects: 400
Study: 28388458

Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to performance situations
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to observation situations
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to interaction situations
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Avoidance responses
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Distinct contributions of fear and avoidance
Number of subjects: 131
Study: 25701812

Group type: EXPERIMENTAL
Intervention: PM mass (<2.5μm) and particle number concentrations (PNCs) in six size fractions during two forty-eight hour sampling periods
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Time of day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Infiltration efficiency
Number of subjects: 96
Study: 23228270

Group type: EXPERIMENTAL
Intervention: Apical preparation size 35.06 to 40.04
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Apical preparation taper from 40.04 to 40.06 in group B
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Apical preparation sizes greater than 40.06
Number of subjects: 155

Group type: COMPARATOR
Intervention: Positive control: maximum volume of 5.25% NaOCl from an open glass vial
Number of subjects: 155

Group type: COMPARATOR
Intervention: Negative control: preparation size of 25.04
Number of subjects: 155
Study: 21570027

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheter (SpeediCath)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Uncoated catheter (Conveen)
Number of subjects: 224
Study: 19591898

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Thalamotomy (TH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 16808770

Group type: EXPERIMENTAL
Intervention: Full disclosure of medical errors
Number of subjects: 407

Group type: COMPARATOR
Intervention: Nondisclosure of medical errors
Number of subjects: 407

Group type: COMPARATOR
Intervention: Missed allergy error condition (Nondisclosure)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Monitoring error condition (Nondisclosure)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Positive physician-patient relationship
Number of subjects: 407

Group type: COMPARATOR
Intervention: Waiving costs associated with the error
Number of subjects: 407
Study: 14698362

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg.mL(‐1) at rate of 0.2 mL.kg ‐1.h ‐1 preceded by a bolus of 2 microg.kg ‐1 (CLON group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg.mL ‐1 and ropivacaine 0.1% at rate of 0.2 mL.kg ‐1.h ‐1 (CLON+ROPIV group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine (both groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 10652960

Group type: EXPERIMENTAL
Intervention: Prednisolone plus 15 mg of menatetrenone, three times per day (Group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisolone alone (Group 1)
Number of subjects: 20
Study: 9315428

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 8364946

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) 320 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) 600 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2439787

Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: atenolol (100 mg)
Number of subjects: 19
Study: 29484546

Group type: EXPERIMENTAL
Intervention: 100-TGF (sodium fluoride NaF associated with tara gum, 1100 mg/L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50-TGF (50% NaF associated with tara gum + 50% free NaF, 1100 mg/L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PC (free NaF, 1100 mg/L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TG (with tara gum and without F)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (without F or tara gum)
Number of subjects: 18
Study: 27596550

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg per day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Voglibose 0.2 mg for 3 times per day
Number of subjects: 56
Study: 24316704

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 1:1.850,000 felypressin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no anesthetic procedures)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 22683041

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (Vo(2))
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: E/A ratio and peak Vo(2)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: E/E' ratio
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: E/A ratio
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Echocardiographic variables
Number of subjects: 2331
Study: 20188357

Group type: EXPERIMENTAL
Intervention: Single cell extraction from karyotypically defined cell lines
Number of subjects: 78
Study: 18216600

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 16424844

Group type: EXPERIMENTAL
Intervention: TEA+GA, poor ventricular function (Group TEA+GA plus PV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TEA+GA, good ventricular function (Group TEA+GA plus GV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GA, poor ventricular function (Group GA plus PV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GA, good ventricular function (Group GA plus GV)
Number of subjects: 80
Study: 12859464

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (50 microg single dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous fentanyl (50 microg single dose)
Number of subjects: 24
Study: 10368939

Group type: EXPERIMENTAL
Intervention: Dual-task condition (lexical decision with auditory probe)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition (lexical decision alone)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dual-task condition (tone detection with auditory probe)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Tones in isolation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increasing SOA (stimulus onset asynchronies)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 2
Study: 8571910

Group type: EXPERIMENTAL
Intervention: 0.8 mg Fe/kg of AMI 227
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.1 mg Fe/kg of AMI 227
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.7 mg Fe/kg of AMI 227
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unenhanced images)
Number of subjects: 16
Study: 1900009

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 312
Study: 6207964

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin and Bleomycin (synergistic effect)
Number of subjects: 0
Study: 30531232

Group type: EXPERIMENTAL
Intervention: 9-week stabilization exercise therapy program, 60 mins/week
Number of subjects: 57
Study: 28552588

Group type: EXPERIMENTAL
Intervention: 4400 IU/d vitamin D3 supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: 400 IU/d vitamin D3 supplementation
Number of subjects: 51
Study: 27400423

Group type: EXPERIMENTAL
Intervention: Active tPCS (10 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active tPCS (20 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tPCS
Number of subjects: 40
Study: 25240992

Group type: EXPERIMENTAL
Intervention: Natural formulation containing tea catechins
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (xylitol-containing)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (catechin and placebo)
Number of subjects: 60
Study: 22218626

Group type: EXPERIMENTAL
Intervention: CRC screening intervention
Number of subjects: 1685
Study: 20031222

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 1636
Study: 17922560

Group type: EXPERIMENTAL
Intervention: UFT (tegafur-uracil) plus leucovorin given as two daily doses (bid)
Number of subjects: 21

Group type: COMPARATOR
Intervention: UFT (tegafur-uracil) plus leucovorin given as three daily doses (tid)
Number of subjects: 21
Study: 16195572

Group type: EXPERIMENTAL
Intervention: Behaviourally specified 'plain English' guidelines
Number of subjects: 84

Group type: COMPARATOR
Intervention: Original text of the NICE public guidelines
Number of subjects: 84
Study: 12734607

Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg once-a-day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10338458

Group type: EXPERIMENTAL
Intervention: High-dose transdermal nitroglycerin (NTG) 50 to 100 mg daily for 12 hours
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7723644

Group type: EXPERIMENTAL
Intervention: Ice-packet vest (V)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Refrigerated headpiece (H)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No cooling (C)
Number of subjects: 6
Study: 2045181

Group type: EXPERIMENTAL
Intervention: High sodium diet (200 meq sodium per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low sodium diet (10 meq sodium per day)
Number of subjects: 17
Study: 6994786

Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Guanethidine (20 mg daily)
Number of subjects: 16
Study: 31126603

Group type: EXPERIMENTAL
Intervention: 3D-printed ultrasound-compatible vascular models (3DPVAM)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Commercial model (CM)
Number of subjects: 49
Study: 28816589

Group type: EXPERIMENTAL
Intervention: Higher acculturation
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Acculturation score increase
Number of subjects: 282
Study: 25739586

Group type: EXPERIMENTAL
Intervention: Insulin aspart (Asp)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin glulisine (Glu)
Number of subjects: 12
Study: 23932834

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 48

Group type: COMPARATOR
Intervention: Acetaminophen (10-15 mg/kg/dose, PO) every 6h as necessary
Number of subjects: 48
Study: 21270331

Group type: EXPERIMENTAL
Intervention: Food deficit
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise deficit
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 19560316

Group type: EXPERIMENTAL
Intervention: JTech PowerTrack II hand-held dynamometer
Number of subjects: 38

Group type: COMPARATOR
Intervention: LIDO WorkSET stationary dynamometer
Number of subjects: 38
Study: 16457935

Group type: EXPERIMENTAL
Intervention: CPREzy feedback device
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no feedback device)
Number of subjects: 224
Study: 15271272

Group type: EXPERIMENTAL
Intervention: Participation in breast cancer prevention clinical trial
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Participation in coronary heart disease prevention clinical trial
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Physicians' recommendations for participation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Perceived risk of disease
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Risk information received from doctors
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Awareness of clinical trials
Number of subjects: 180
Study: 12616844

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0